GB201713765D0 - Modified adenovirus - Google Patents

Modified adenovirus

Info

Publication number
GB201713765D0
GB201713765D0 GBGB1713765.4A GB201713765A GB201713765D0 GB 201713765 D0 GB201713765 D0 GB 201713765D0 GB 201713765 A GB201713765 A GB 201713765A GB 201713765 D0 GB201713765 D0 GB 201713765D0
Authority
GB
United Kingdom
Prior art keywords
modified adenovirus
adenovirus
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1713765.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Priority to GBGB1713765.4A priority Critical patent/GB201713765D0/en
Priority to EP17771343.5A priority patent/EP3503918B1/en
Priority to KR1020197008941A priority patent/KR102427563B1/ko
Priority to MYPI2019000750A priority patent/MY197324A/en
Priority to EA201990183A priority patent/EA201990183A1/ru
Priority to PCT/EP2017/071674 priority patent/WO2018041838A1/en
Priority to IL264902A priority patent/IL264902B2/en
Priority to CA3033267A priority patent/CA3033267A1/en
Priority to CN201780057768.4A priority patent/CN110214025B/zh
Priority to PCT/EP2017/071655 priority patent/WO2018041827A1/en
Priority to JP2019507924A priority patent/JP2019532621A/ja
Priority to EP23170482.6A priority patent/EP4273252A3/en
Priority to SG11201901716TA priority patent/SG11201901716TA/en
Priority to US16/329,125 priority patent/US12258417B2/en
Priority to US16/329,098 priority patent/US12049513B2/en
Priority to IL303187A priority patent/IL303187A/en
Priority to AU2017320776A priority patent/AU2017320776B2/en
Priority to JP2019532192A priority patent/JP7212620B2/ja
Priority to CN202410956740.6A priority patent/CN119614520A/zh
Priority to BR112019003866-3A priority patent/BR112019003866A2/pt
Priority to ES17771344T priority patent/ES2983916T3/es
Priority to KR1020227026101A priority patent/KR102491752B1/ko
Priority to MX2019002328A priority patent/MX2019002328A/es
Priority to SG11201901715UA priority patent/SG11201901715UA/en
Priority to CN201780056486.2A priority patent/CN109862912B/zh
Priority to CN202410962886.1A priority patent/CN119592523A/zh
Priority to CA3034517A priority patent/CA3034517A1/en
Priority to EP17771344.3A priority patent/EP3503919B1/en
Publication of GB201713765D0 publication Critical patent/GB201713765D0/en
Priority to CN201880055171.0A priority patent/CN111712257B/zh
Priority to BR112020003842-3A priority patent/BR112020003842A2/pt
Priority to UAA202000400A priority patent/UA126972C2/uk
Priority to CN202311294743.XA priority patent/CN119432918A/zh
Priority to MYPI2020000962A priority patent/MY197586A/en
Priority to MX2020002158A priority patent/MX2020002158A/es
Priority to JP2020511748A priority patent/JP7280244B2/ja
Priority to EA202090124A priority patent/EA202090124A1/ru
Priority to CA3073480A priority patent/CA3073480A1/en
Priority to PCT/EP2018/073160 priority patent/WO2019043020A1/en
Priority to KR1020207005898A priority patent/KR20200037826A/ko
Priority to SG11202001537QA priority patent/SG11202001537QA/en
Priority to US16/641,696 priority patent/US11840702B2/en
Priority to EP24173800.4A priority patent/EP4403227A3/en
Priority to AU2018322776A priority patent/AU2018322776B2/en
Priority to EP18773082.5A priority patent/EP3675904A1/en
Priority to ZA2019/00644A priority patent/ZA201900644B/en
Priority to MX2023008779A priority patent/MX2023008779A/es
Priority to CL2019000510A priority patent/CL2019000510A1/es
Priority to PH12019500436A priority patent/PH12019500436A1/en
Priority to CONC2019/0002371A priority patent/CO2019002371A2/es
Priority to ZA2020/00388A priority patent/ZA202000388B/en
Priority to CONC2020/0001930A priority patent/CO2020001930A2/es
Priority to IL272872A priority patent/IL272872B/en
Priority to SA520411426A priority patent/SA520411426B1/ar
Priority to PH12020500386A priority patent/PH12020500386A1/en
Priority to JP2022130173A priority patent/JP7525558B2/ja
Priority to US18/481,833 priority patent/US20240175052A1/en
Priority to US18/744,059 priority patent/US20250026851A1/en
Priority to JP2024114614A priority patent/JP2024147722A/ja
Priority to AU2025200140A priority patent/AU2025200140A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1713765.4A 2016-08-29 2017-08-28 Modified adenovirus Ceased GB201713765D0 (en)

Priority Applications (59)

Application Number Priority Date Filing Date Title
GBGB1713765.4A GB201713765D0 (en) 2017-08-28 2017-08-28 Modified adenovirus
EP17771343.5A EP3503918B1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
KR1020197008941A KR102427563B1 (ko) 2016-08-29 2017-08-29 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
MYPI2019000750A MY197324A (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell activator
EA201990183A EA201990183A1 (ru) 2017-08-28 2017-08-29 Аденовирус, вооруженный биспецифичным активатором т-клеток (bite)
PCT/EP2017/071674 WO2018041838A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
IL264902A IL264902B2 (en) 2016-08-29 2017-08-29 Adenovirus with bispecific T cell activator
CA3033267A CA3033267A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
CN201780057768.4A CN110214025B (zh) 2016-08-29 2017-08-29 携带双特异性t细胞衔接器的腺病毒
PCT/EP2017/071655 WO2018041827A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
JP2019507924A JP2019532621A (ja) 2016-08-29 2017-08-29 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
EP23170482.6A EP4273252A3 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
SG11201901716TA SG11201901716TA (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
US16/329,125 US12258417B2 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific T cell engager
US16/329,098 US12049513B2 (en) 2016-08-29 2017-08-29 Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
IL303187A IL303187A (en) 2016-08-29 2017-08-29 Adenovirus with bispecific T cell activator
AU2017320776A AU2017320776B2 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific T cell activator
JP2019532192A JP7212620B2 (ja) 2016-08-29 2017-08-29 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス
CN202410956740.6A CN119614520A (zh) 2016-08-29 2017-08-29 携带双特异性t细胞衔接器的腺病毒
BR112019003866-3A BR112019003866A2 (pt) 2016-08-29 2017-08-29 adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
ES17771344T ES2983916T3 (es) 2016-08-29 2017-08-29 Adenovirus armado con acoplador de célula T biespecífica
KR1020227026101A KR102491752B1 (ko) 2016-08-29 2017-08-29 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
MX2019002328A MX2019002328A (es) 2016-08-29 2017-08-29 Adenovirus armado con captador biespecífico de linfocitos t (bite).
SG11201901715UA SG11201901715UA (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager (bite)
CN201780056486.2A CN109862912B (zh) 2016-08-29 2017-08-29 携带双特异性t细胞衔接器的腺病毒
CN202410962886.1A CN119592523A (zh) 2016-08-29 2017-08-29 携带双特异性t细胞衔接器的腺病毒
CA3034517A CA3034517A1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell activator
EP17771344.3A EP3503919B1 (en) 2016-08-29 2017-08-29 Adenovirus armed with bispecific t cell engager
CN201880055171.0A CN111712257B (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒
BR112020003842-3A BR112020003842A2 (pt) 2017-08-28 2018-08-28 adenovírus armado com aglutinante biespecífico de células t (bite)
UAA202000400A UA126972C2 (uk) 2017-08-28 2018-08-28 Аденовірус, озброєний біспецифічним рекрутером t-клітин (bite)
CN202311294743.XA CN119432918A (zh) 2017-08-28 2018-08-28 携带双特异性T细胞衔接器（BiTE）的腺病毒
MYPI2020000962A MY197586A (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific t cell engager (bite)
MX2020002158A MX2020002158A (es) 2017-08-28 2018-08-28 Adenovirus armado con captador biespecifico de linfocitos t (bite).
JP2020511748A JP7280244B2 (ja) 2017-08-28 2018-08-28 二重特異性ｔ細胞アクチベーターを搭載したアデノウイルス
EA202090124A EA202090124A1 (ru) 2017-08-28 2018-08-28 Аденовирус, вооруженный биспецифическим рекрутером t-клеток (bite)
CA3073480A CA3073480A1 (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific t cell engager (bite)
PCT/EP2018/073160 WO2019043020A1 (en) 2017-08-28 2018-08-28 ADENOVIRUS EQUIPPED WITH A BISPECIFIC T CELL ACTIVATOR (BITE)
KR1020207005898A KR20200037826A (ko) 2017-08-28 2018-08-28 이중특이성 T 세포 관여자(BiTE)를 갖춘 아데노바이러스
SG11202001537QA SG11202001537QA (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific t cell engager (bite)
US16/641,696 US11840702B2 (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific T cell activator
EP24173800.4A EP4403227A3 (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific t cell engager (bite)
AU2018322776A AU2018322776B2 (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific T cell engager (BiTE)
EP18773082.5A EP3675904A1 (en) 2017-08-28 2018-08-28 Adenovirus armed with bispecific t cell engager (bite)
ZA2019/00644A ZA201900644B (en) 2016-08-29 2019-01-30 Adenovirus armed with bispecific t cell engager (bite)
MX2023008779A MX2023008779A (es) 2016-08-29 2019-02-26 Adenovirus armado con un activador biespecifico de linfocitos t.
CL2019000510A CL2019000510A1 (es) 2016-08-29 2019-02-26 Adenovirus armado con un activador de células t biespecífico (bite).
PH12019500436A PH12019500436A1 (en) 2016-08-29 2019-02-28 Adenovirus armed with bispecific t cell engager (bite)
CONC2019/0002371A CO2019002371A2 (es) 2016-08-29 2019-03-14 Adenovirus armado con captador biespecífico de linfocitos t (bite)
ZA2020/00388A ZA202000388B (en) 2017-08-28 2020-01-20 Adenovirus armed with bispecific t cell engager (bite)
CONC2020/0001930A CO2020001930A2 (es) 2017-08-28 2020-02-21 Adenovirus armado con captador biespecífico de linfocitos t (bite)
IL272872A IL272872B (en) 2017-08-28 2020-02-24 Pentavirus with bispecific t-cell activator (bite)
SA520411426A SA520411426B1 (ar) 2017-08-28 2020-02-27 فيروس غدّي مزود بموصل خلايا تائية ثنائية النوعية
PH12020500386A PH12020500386A1 (en) 2017-08-28 2020-02-27 Adenovirus armed with bispecific t cell engager (bite)
JP2022130173A JP7525558B2 (ja) 2016-08-29 2022-08-17 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス
US18/481,833 US20240175052A1 (en) 2017-08-28 2023-10-05 Adenovirus armed with bispecific T cell activator
US18/744,059 US20250026851A1 (en) 2016-08-29 2024-06-14 Adenovirus armed with bispecific t cell activator
JP2024114614A JP2024147722A (ja) 2016-08-29 2024-07-18 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
AU2025200140A AU2025200140A1 (en) 2016-08-29 2025-01-09 Adenovirus armed with bispecific T cell activator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713765.4A GB201713765D0 (en) 2017-08-28 2017-08-28 Modified adenovirus

Publications (1)

Publication Number Publication Date
GB201713765D0 true GB201713765D0 (en) 2017-10-11

Family

ID=60037191

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1713765.4A Ceased GB201713765D0 (en) 2016-08-29 2017-08-28 Modified adenovirus

Country Status (20)

Country Link
US (2) US11840702B2 (enExample)
EP (2) EP4403227A3 (enExample)
JP (1) JP7280244B2 (enExample)
KR (1) KR20200037826A (enExample)
CN (2) CN119432918A (enExample)
AU (1) AU2018322776B2 (enExample)
BR (1) BR112020003842A2 (enExample)
CA (1) CA3073480A1 (enExample)
CO (1) CO2020001930A2 (enExample)
EA (2) EA201990183A1 (enExample)
GB (1) GB201713765D0 (enExample)
IL (1) IL272872B (enExample)
MX (1) MX2020002158A (enExample)
MY (1) MY197586A (enExample)
PH (1) PH12020500386A1 (enExample)
SA (1) SA520411426B1 (enExample)
SG (1) SG11202001537QA (enExample)
UA (1) UA126972C2 (enExample)
WO (1) WO2019043020A1 (enExample)
ZA (1) ZA202000388B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
EP3916098A1 (en) * 2020-05-25 2021-12-01 Medizinische Hochschule Hannover Adenovirus for anti-tumour therapy
US20230272420A1 (en) * 2020-06-04 2023-08-31 Devacell, Inc. Recombinant viruses, surface-engineered delivery systems and related methods
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR102799318B1 (ko) 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
CN115161293B (zh) * 2021-04-01 2024-11-15 南京惟亚德生物医药有限公司 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN119072325A (zh) 2022-02-11 2024-12-03 治纳辅医药科技有限公司 包含含有il-12和抗fap抗体的融合蛋白以及抗癌剂的用于癌症治疗的药物组合物
KR20230162310A (ko) 2022-05-20 2023-11-28 주식회사 카나프테라퓨틱스 Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
EP4562028A1 (en) 2022-07-28 2025-06-04 Akamis Bio Limited Virus encoding transgenes to complement cellular therapy
EP4581055A1 (en) 2022-08-31 2025-07-09 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2026117753A1 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Viral vectors for expression of synthetic cancer antigens and chemokine and related methods and uses
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5587299A (en) 1994-04-20 1996-12-24 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
ATE374821T1 (de) 1997-02-20 2007-10-15 Univ Johns Hopkins Med Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
AU774076C (en) 1998-12-09 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
WO2000061726A1 (fr) 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
ATE291633T1 (de) 1999-06-01 2005-04-15 Univ Washington Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1301612A2 (en) 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
EP1646717A4 (en) 2003-07-18 2006-12-20 Onyx Pharma Inc ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
ES2358204T3 (es) 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
WO2006039045A2 (en) 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US20110086005A1 (en) 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
KR101837053B1 (ko) * 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2486137B1 (en) 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
AU2011292120B2 (en) 2010-08-16 2015-07-30 Salk Institute For Biological Studies Adenoviral assembly method
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
JP2015507604A (ja) 2011-11-14 2015-03-12 リジェネレイティブ サイエンシーズ， エルエルシー 懸濁粒子送達システムおよび方法
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB2519564A (en) 2013-10-24 2015-04-29 Shared Band Ltd Multicast transmission over bonded broadband
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
KR20170044194A (ko) 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
WO2016146894A1 (en) 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
AU2017233072B2 (en) 2016-03-18 2020-12-24 Nantcell, Inc. Multimodal vector for dendritic cell infection
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
SG11202001537QA (en) 2020-03-30
EP3675904A1 (en) 2020-07-08
PH12020500386A1 (en) 2021-01-04
US11840702B2 (en) 2023-12-12
US20240175052A1 (en) 2024-05-30
EA201990183A1 (ru) 2019-07-31
JP2020531032A (ja) 2020-11-05
EA202090124A1 (ru) 2020-12-10
UA126972C2 (uk) 2023-03-01
KR20200037826A (ko) 2020-04-09
ZA202000388B (en) 2021-01-27
BR112020003842A2 (pt) 2020-09-08
SA520411426B1 (ar) 2023-02-20
EP4403227A2 (en) 2024-07-24
CN111712257B (zh) 2023-10-27
AU2018322776A1 (en) 2020-03-12
MX2020002158A (es) 2020-07-20
US20200216859A1 (en) 2020-07-09
JP7280244B2 (ja) 2023-05-23
WO2019043020A1 (en) 2019-03-07
CN111712257A (zh) 2020-09-25
AU2018322776B2 (en) 2023-04-06
EP4403227A3 (en) 2024-10-30
CA3073480A1 (en) 2019-03-07
CN119432918A (zh) 2025-02-14
IL272872A (en) 2020-04-30
CO2020001930A2 (es) 2020-06-09
IL272872B (en) 2021-05-31
MY197586A (en) 2023-06-26

Similar Documents

Publication Publication Date Title
DK3499914T3 (en) Høreapparatsystem
DK3734167T3 (en) Airconditionsystem
GB201703129D0 (en) Quibbler
IL273493A (en) Modified CAR-T
DK3700925T3 (en) Hidtil ukendt t-cellereceptor
DK3630041T3 (en) Stimulationsapparat
DK3704866T3 (en) Datatransmissionssystem
DK3615457T3 (en) Transportcontainer
GB201700825D0 (en) Poliovaccine
DK3485765T3 (en) Computerbord
DK3401557T3 (en) Træskrue
DK3718525T3 (en) Motoriseret asssistancesystem
GB201702641D0 (en) Easpagnolette
GB201718871D0 (en) Composition
DK3618761T3 (en) Intrakorporalt perfusionssystem
GB201709193D0 (en) Combination
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
DK3425793T3 (en) Tagsystem
GB201614607D0 (en) Modified adenovirus
DK3351149T3 (en) Syltetøjsfontæne
GB201713289D0 (en) Combination
GB201706929D0 (en) Combination
AU201715236S (en) Striplight
GB201707508D0 (en) Modified bulgeomers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)